Mast cell–targeting therapies in mast cell activation syndromes University of Antwerp
Purpose of Review Provide an overview of the expanding landscape of mast cell (MC)–targeting treatments in mast cell activation syndromes (MCAS). Recent Findings Tyrosine-kinase inhibitors (TKIs) targeting wild-type and mutated KIT can efficiently induce MC depletion. Avapritinib and midostaurin can also temper IgE-mediated degranulation. Avapritinib has been recently approved by the FDA for the treatment of indolent systemic mastocytosis (ISM). ...